ARTL
Price:
$1.2001
Market Cap:
$3.87M
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to i...[Read more]
Industry
Biotechnology
IPO Date
2019-06-21
Stock Exchange
NASDAQ
Ticker
ARTL
According to Artelo Biosciences, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.36. This represents a change of -48.15% compared to the average of -0.69 of the last 4 quarters.
The mean historical PE Ratio of Artelo Biosciences, Inc. over the last ten years is -64.81. The current -0.36 PE Ratio has changed -44.45% with respect to the historical average. Over the past ten years (40 quarters), ARTL's PE Ratio was at its highest in in the November 2013 quarter at 0. The PE Ratio was at its lowest in in the August 2014 quarter at -24958.25.
Average
-64.81
Median
-2.50
Minimum
-291.37
Maximum
-0.76
Discovering the peaks and valleys of Artelo Biosciences, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 199.49%
Maximum Annual PE Ratio = -0.76
Minimum Annual Increase = -88.31%
Minimum Annual PE Ratio = -291.37
Year | PE Ratio | Change |
---|---|---|
2022 | -0.83 | -63.78% |
2021 | -2.29 | 199.49% |
2020 | -0.76 | -60.59% |
2019 | -1.94 | -22.44% |
2018 | -2.50 | -88.31% |
2017 | -21.38 | -85.55% |
2016 | -148.00 | -49.20% |
2015 | -291.37 | 155.13% |
The current PE Ratio of Artelo Biosciences, Inc. (ARTL) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.29
5-year avg
-1.66
10-year avg
-64.81
Artelo Biosciences, Inc.’s PE Ratio is greater than Aileron Therapeutics, Inc. (-2.21), less than Histogen Inc. (-0.10), greater than Curis, Inc. (-0.61), less than Timber Pharmaceuticals, Inc. (-0.07), less than Salarius Pharmaceuticals, Inc. (-0.14), greater than Vaccinex, Inc. (-0.58), greater than Fresh Tracks Therapeutics, Inc. (-0.78), less than Basilea Pharmaceutica AG (0), less than Ascletis Pharma Inc. (25.48), greater than AVAX Technologies, Inc. (-55.70), less than Brii Biosciences Limited (-0.00), greater than Pasithea Therapeutics Corp. (-1.43), less than Nutriband Inc. (-0.27), greater than ZIVO Bioscience, Inc. (-6.76), greater than MediciNova, Inc. (-2.46), greater than Eliem Therapeutics, Inc. (-12.61), greater than Akari Therapeutics, Plc (-3.49), greater than Axcella Health Inc. (-1.55), greater than Magenta Therapeutics, Inc. (-10.73), less than null (-0.04),
Company | PE Ratio | Market cap |
---|---|---|
-2.21 | $60.66M | |
-0.10 | $939.79K | |
-0.61 | $29.78M | |
-0.07 | $1.18M | |
-0.14 | $2.15M | |
-0.58 | $9.73M | |
-0.78 | $4.42M | |
0 | $621.33M | |
25.48 | $149.08M | |
-55.70 | $6.42M | |
-0.00 | $91.63M | |
-1.43 | $4.37M | |
-0.27 | $47.76M | |
-6.76 | $37.03M | |
-2.46 | $103.00M | |
-12.61 | $495.57M | |
-3.49 | $35.02M | |
-1.55 | $0 | |
-10.73 | $42.44M | |
-0.04 | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Artelo Biosciences, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Artelo Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Artelo Biosciences, Inc.'s PE Ratio?
How is the PE Ratio calculated for Artelo Biosciences, Inc. (ARTL)?
What is the highest PE Ratio for Artelo Biosciences, Inc. (ARTL)?
What is the 3-year average PE Ratio for Artelo Biosciences, Inc. (ARTL)?
What is the 5-year average PE Ratio for Artelo Biosciences, Inc. (ARTL)?
How does the current PE Ratio for Artelo Biosciences, Inc. (ARTL) compare to its historical average?